文献速递分子诊断临床微生物临床免疫

脑膜炎球菌推断疫苗抗原反应性(MenDeVAR)指数:利用基因组数据的快速可及工具

Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool That Exploits Genomic Data in Public Health and Clinical Microbiology Applications.
PubMed 文献 · J Clin Microbiol · 2020-12-17

为便于非基因组学专家解读全基因组序列数据,研究者整合已发表的基因组与实验数据,开发了MenDeVAR指数并公开于PubMLST。该指数利用IMD分离株或临床标本的基因组序列,快速提供疫苗抗原变异体存在及可能免疫交叉反应性的循证信息,辅助个体病例、暴发管理和公共卫生疫苗项目评估。

要点

  • MenDeVAR指数基于全基因组或单基因序列快速评估脑膜炎球菌疫苗抗原变异体及交叉反应性。
  • 该工具旨在帮助非基因组学专家在临床和公共卫生场景中解读序列数据。
  • MenDeVAR指数公开可用,开发时咨询但独立于4CMenB和rLP2086疫苗制造商。

核心结论

  • MenDeVAR指数可快速提供脑膜炎球菌疫苗抗原变异体存在及可能免疫交叉反应性的循证信息。

研究设计与样本

  • 研究者整合已发表的基因组与实验数据,开发并实施MenDeVAR指数,公开于PubMLST。

主要发现

  • 利用IMD分离株或临床标本的全基因组序列或单基因序列,MenDeVAR指数可快速评估疫苗抗原变异体的存在和免疫交叉反应性。

临床怎么用

  • 非基因组学专家可用MenDeVAR指数评估个体病例的疫苗可能反应性、暴发管理或公共卫生疫苗项目评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As microbial genomics makes increasingly important contributions to clinical and public health microbiology, the interpretation of whole-genome sequence data by nonspecialists becomes essential. In the absence of capsule-based vaccines, two protein-based vaccines have been used for the prevention of invasive serogroup B meningococcal disease (IMD) since their licensure in 2013 and 2014. These vaccines have different components and different levels of coverage of meningococcal variants. Hence, decisions regarding which vaccine to use in managing serogroup B IMD outbreaks require information about the index case isolate, including (i) the presence of particular vaccine antigen variants, (ii) the expression of vaccine antigens, and (iii) the likely susceptibility of its antigen variants to antibody-dependent bactericidal killing. To obtain this information requires a multitude of laboratory assays, impractical in real-time clinical settings, where the information is most urgently needed. To facilitate assessment for public health and clinical purposes, we synthesized genomic and experimental data from published sources to develop and implement the Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index, which is publicly available on PubMLST (https://pubmlst.org). Using whole-genome sequences or individual gene sequences obtained from IMD isolates or clinical specimens, the MenDeVAR Index provides rapid evidence-based information on the presence and possible immunological cross-reactivity of different meningococcal vaccine antigen variants. The MenDeVAR Index enables practitioners who are not genomics specialists to assess the likely reactivity of vaccines for individual cases, outbreak management, or the assessment of public health vaccine programs. The MenDeVAR Index has been developed in consultation with, but independently of, both the 4CMenB (Bexsero; GSK) and rLP2086 (Trumenba; Pfizer, Inc.) vaccine manufacturers.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Rodrigues CMC, Jolley KA, Smith A, et al. Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) Index: a Rapid and Accessible Tool That Exploits Genomic Data in Public Health and Clinical Microbiology Applications. J Clin Microbiol. 2020. PMID: 33055180. doi:10.1128/JCM.02161-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。